Turing Pharmaceuticals, the company that elicited public outcry after raising the price of its drug Daraprim by 5,000 percent overnight, faces an antitrust inquiry regarding its marketing and distribution of the drug, according to a report from JD Supra.
Martin Shkreli, the 32-year-old CEO of Turing Pharmaceuticals, headed the company’s purchase of Daraprim in August from Impax Laboratories for $55 million. Daraprim is an antiparasite medication developed 62 years ago.
In September, he increased the price of the drug from $13.50 to $750 per pill overnight, a decision that precipitated public backlash. Ultimately, Mr. Shkreli backed down and said he would lower the price of the drug to an undisclosed amount, according to the report.
However, Turing’s original announcement and subsequent public scrutiny captured the attention of the New York Attorney General’s office. According to the report, the antitrust chief under Attorney General Eric Schneiderman sent Mr. Shkreli and Turing a letter requesting he contact the Attorney General’s office to discuss the company’s distribution channel.
Full content: JD Supra
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Justice Department Moves to End NCAA Transfer Rule
May 30, 2024 by
CPI
Kenya’s Competition Authority Proposes Tougher Regulations on Big Tech
May 30, 2024 by
CPI
KKR Secures EU Antitrust Approval for $24 Billion Acquisition of Telecom Italia’s Fixed-Line Network
May 30, 2024 by
CPI
European Court Sides with Tech Giants in Italian Regulatory Dispute
May 30, 2024 by
CPI
US Steel and Nippon Steel Secure International Approvals for $14.9B Merger
May 30, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI